Up or Down, Three Biotechs that Will Face Major Decisions Soon
Although Foolish investors take the long view, the biotechnology industry is marked by seismic events that can abruptly alter stock prices.
Soon, Sarepta Therapeutics (NASDAQ: SRPT) will face a make-or-break moment in front of an FDA advisory committee that will discuss the approvability of its lead candidate. The FDA isn't required to follow independent committee recommendations, but it usually does. The next several weeks will also be tense for Vertex Pharmaceuticals (NASDAQ: VRTX) shareholders, as the company awaits a regulatory decision expected Feb. 6 or possibly sooner. Also in February, Flexion Therapeutics (NASDAQ: FLXN) is expected to announce phase 3 results for a drug that missed the mark last year.
Soon, Sarepta Therapeutics (NASDAQ: SRPT) will face a make-or-break moment in front of an FDA advisory committee that will discuss the approvability of its lead candidate. The FDA isn't required to follow independent committee recommendations, but it usually does. The next several weeks will also be tense for Vertex Pharmaceuticals (NASDAQ: VRTX) shareholders, as the company awaits a regulatory decision expected Feb. 6 or possibly sooner. Also in February, Flexion Therapeutics (NASDAQ: FLXN) is expected to announce phase 3 results for a drug that missed the mark last year.